One of AstraZeneca's top drugs, the diabetes med Farxiga, has been given fast track status by the U.S. Food and Drug Administration as a method to prevent heart and kidney failure in patients with chronic kidney disease.
Farxiga is approved in the U.S. to treat type-2 diabetes but earlier in the year, regulators declined to approve Farxiga as a supplement to insulin in adults with type-1 diabetes where insulin alone was not able to control blood sugar levels.
Farxiga will compete with Novo Nordisk’s Victoza and Eli Lilly and Boehringer Ingelheim’s Jardiance.
Read the Reueters report